Characteristics of Cytokine Response in Patients With Temporomandibular Disorders Treated With Occlusal Splint Therapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Change in cytokines level (IL-1beta, IL-13, IL-6, IL-7, IL-8, TNF alpha) in gingival crevicular fluid (GCF) after stabilization occlusal splint therapy
研究概览
简要总结
The goal of this intervention study is to determine the effect of occlusal splint (OS) therapy on the concentration of inflammatory cytokines in serum and gingival crevicular fluid (GCF) in patients with temporomandibular disorders (TMDs).
Aims are:
- to determine cytokines level in GCF and serum before and after OS therapy
- to determine the degree of psychosocial dysfunction and oral health-related quality of life before and after OS therapy
- investigate the correlation between cytokines level in GCF and serum
- to determine the effect of OS on treatment outcomes, pain intensity, dysfunction, and psychosocial status of patients with painful TMD. Participants will be asked to complete self-assessment questionnaires, and GCF and blood samples will be collected before beginning of the OS therapy and at follow-up examinations one month and two months after.
详细描述
Temporomandibular disorder (TMD) is a multifactorial disease with complex etiopathogenesis. The main symptoms are persistent pain in the masticatory muscles and preauricular region, limitations in jaw function, and sounds in the temporomandibular joints. The most commonly used therapy is the occlusal splint (OS). The therapeutic effect of OS is attributed to various factors, however the exact mechanism is still unknown. One of the potential diagnostic methods is the use of molecular biomarkers. Studies have demonstrated a correlation between inflammatory cytokines and pain in TMD patients compared to healthy controls. Molecular biomarker levels can be determined from tissue samples and body fluids. Gingival crevicular fluid (GCF) is a serum exudate that enters the gingival sulcus from the gingival plexus of blood vessels and contains proteins, various cell types, electrolytes, cytokines, etc. Considering its composition, wide availability, non-invasive method, and speed of collection, GCF could be a new source of TMD biomarkers with potential diagnostic, prognostic, and therapeutic purposes.
Participants diagnosed with myalgia, arthralgia, headache attributed to TMP and/or painful disk displacement (with and without reduction) according to DC /TMD will be included in the study. Participants will be asked to complete self-assessment questionnaires: Graded Chronic Pain Scale (v2), Jaw Functional Limitation Scale-20, Patient Health Questionnaire-9, Genaral Anxiety Disorder-7, Patient Health Questionnaire-15, Oral Behaviors Checklist, Oral health Impact Profile, and Perceived Stress Scale-10. The occlusal splints will be fabricated from hard acrylic resin by the same dental technician in the dental laboratory. The GCF sample will be collected from the sulcus using sterile tweezers and sterile paper sticks and placed in an Eppendorf tube containing 250 µl of 0.9% NaCl solution. Blood samples will be collected in Vacutainers and stored at +4°C until centrifugation. For multicomplex quantitative analysis of proinflammatory cytokines (interleukin 1 beta (IL -1β), interleukin 6 (IL - 6), interleukin 7 (IL -7), interleukin 8 (IL -8), interleukin 13 (IL -13), tumor necrosis factor alpha (TNF-α)), adapted ProcartaPlex multiplex assays will be used.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •signed informed consent
- •TMP pain screening scores ≥ 3
- •patients with natural teeth
- •diagnoses: myalgia, arthralgia, headache attributed to TMP and painful disc displacement (with and without reduction) according to axis I diagnostic criteria for temporomandibular disorders (DK/TMP)
排除标准
- •degenerative joint disease and subluxation of the temporomandibular joint (TMJ)
- •head trauma
- •orofacial pain not associated with temporomandibular disorders
- •patients with fixed or removable prostheses
- •patients who are currently undergoing orthodontic therapy and/or using occlusal splints
- •patients who used anti-inflammatory drugs and muscle relaxants 48 hours before data collection, and patients who use drugs with an impact on the immune system (such as antiproliferative immunosuppressants, corticosteroids and other immunosuppressants, antirheumatic drugs, DMARDs, anti-lymphocyte monoclonal antibodies and other immunomodulating drugs , antidepressants, antiepileptics)
- •periodontitis
- •pregnancy
结局指标
主要结局
Change in cytokines level (IL-1beta, IL-13, IL-6, IL-7, IL-8, TNF alpha) in gingival crevicular fluid (GCF) after stabilization occlusal splint therapy
时间窗: Baseline, one month, three months
Custom ProcartaPlex Multiplex assays will be used for multicomplex quantitative analysis of inflammatory mediators. The entire protocol will be carried out according to the instructions of the manufacturer of eBioscience, Affymetrix.
Change in cytokines level (IL-1beta, IL-13, IL-6, IL-7, IL-8, TNF alpha) in circulating blood after stabilization occlusal splint therapy
时间窗: Baseline, one month, three months
Custom ProcartaPlex Multiplex assays will be used for multicomplex quantitative analysis of inflammatory mediators. The entire protocol will be carried out according to the instructions of the manufacturer of eBioscience, Affymetrix.
次要结局
- Change in perceived stress levels in TMD patients after stabilization occlusal splint therapy(Baseline, one month, three months)
- Change in the presence of parafunctional behaviors in patients with TMD after stabilization occlusal splint therapy(Baseline, one month, three months)
- Change in jaw function limitation in patients with TMD after stabilization occlusal splint therapy(Baseline, one month, three months)
- Change in pain free opening, maximum unassisted opening and maximum assisted opening after stabilization occlusal splint therapy(Baseline, one month, three months)
- Change in oral health-related quality of life in TMD patients after stabilization occlusal splint therapy(Baseline, one month, three months)
- Change in depressed mood in patients with TMD after stabilization occlusal splint therapy(Baseline, one month, three months)
- Change in physical symptoms in patients with TMD after stabilization occlusal splint therapy(Baseline, one month, three months)
- Change in pain intensity and pain-related disability after stabilization occlusal splint therapy(Baseline, one month, three months)
- Change in anxious feelings and behavior in patients with TMD after stabilization occlusal splint therapy(Baseline, one month, three months)
研究者
Renata Sikora, DMD
DMD, Assistant, Faculty of Dental Medicine and Health
Josip Juraj Strossmayer University of Osijek